Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage of COVID-19 Research
Closing enrollment for this study is an important step to better understanding the clinical benefit of non-invasive vagus nerve stimulation (nVNS) and how it can help patients suffering from COVID-19 respiratory distress.
- Closing enrollment for this study is an important step to better understanding the clinical benefit of non-invasive vagus nerve stimulation (nVNS) and how it can help patients suffering from COVID-19 respiratory distress.
- In fact, the most downloaded 2020 article in the Journal of Neuromodulation was The Use of Noninvasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID19: A Theoretical Hypothesis and Early Clinical Experience .
- Research should be focused on identifying novel therapies with strong clinical rationale that can be used throughout the course of disease.
- electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology.